cAC10-Gly5-PNU

cAC10-Gly5-PNU is an experimental antibody-drug conjugate (ADC) targeting CD30, developed by NBE-Therapeutics using its proprietary Sortase-Mediated Antibody Conjugation (SMAC) technology. It consists of the anti-CD30 monoclonal antibody cAC10 (the antibody component of brentuximab vedotin) site-specifically conjugated to a derivative of the highly potent anthracycline PNU-159682 via a noncleavable pentaglycine (Gly5) linker. The SMAC technology enables the production of homogeneous ADCs with a drug-to-antibody ratio (DAR) of approximately 4.0. The PNU-159682 payload is a liver metabolite of nemorubicin and is significantly more potent than standard microtubule-disrupting agents, acting as a DNA-intercalating agent and topoisomerase II inhibitor. Preclinical studies in CD30-positive non-Hodgkin lymphoma models (such as Karpas-299) have shown that cAC10-Gly5-PNU is highly stable in serum and exhibits superior antitumor activity compared to conventional ADCs like Adcetris, particularly in aggressive disease models.

Other names

cAC10-Gly5-EDA-PNUcAC-10-Gly5-EDA-PNUcAC 10-Gly5-EDA-PNUanti-CD30-Gly5-PNUanti-CD-30-Gly5-PNUanti-CD 30-Gly5-PNUcAC10-PNUcAC-10-PNUcAC 10-PNU